> top > docs > PMC:7799378 > spans > 21832-22448 > annotations

PMC:7799378 / 21832-22448 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
877 62-66 Gene denotes G6PD Gene:2539
878 70-76 Species denotes humans Tax:9606
879 333-341 Species denotes patients Tax:9606
880 16-24 Disease denotes COVID-19 MESH:C000657245
881 160-168 Disease denotes COVID-19 MESH:C000657245
882 241-256 Disease denotes G6PD deficiency MESH:D005955
883 306-314 Disease denotes COVID-19 MESH:C000657245
884 318-332 Disease denotes G6PD-deficient MESH:D005955
885 350-365 Disease denotes G6PD deficiency MESH:D005955
886 550-565 Disease denotes G6PD deficiency MESH:D005955
887 598-606 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T175 0-132 Sentence denotes The severity of COVID-19 is influenced by genetic variants of G6PD in humans, which is related to an impaired immune response [111].
T176 133-257 Sentence denotes It has been predicted that COVID-19 will spread more widely in areas or countries with a high prevalence of G6PD deficiency.
T177 258-342 Sentence denotes This concern poses a serious challenge to treat COVID-19 in G6PD-deficient patients.
T178 343-542 Sentence denotes Severe G6PD deficiency is associated with an altered immune response, including NET formation, inflammasome activation, and bactericidal activity as well as an antiviral response [9–11,42,85,95,110].
T179 543-616 Sentence denotes Hence, G6PD deficiency presents a challenge during the COVID-19 pandemic.